Biomarin Pharmaceutical Inc
NASDAQ:BMRN
Biomarin Pharmaceutical Inc
Revenue
Biomarin Pharmaceutical Inc
Revenue Peer Comparison
Competitive Revenue Analysis
Latest Figures & CAGR of Competitors
Company | Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
Revenue
$2.5B
|
CAGR 3-Years
10%
|
CAGR 5-Years
10%
|
CAGR 10-Years
16%
|
|
Abbvie Inc
NYSE:ABBV
|
Revenue
$54.3B
|
CAGR 3-Years
6%
|
CAGR 5-Years
11%
|
CAGR 10-Years
11%
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Revenue
$27.5B
|
CAGR 3-Years
2%
|
CAGR 5-Years
4%
|
CAGR 10-Years
7%
|
|
Amgen Inc
NASDAQ:AMGN
|
Revenue
$28.2B
|
CAGR 3-Years
4%
|
CAGR 5-Years
3%
|
CAGR 10-Years
4%
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Revenue
$9.9B
|
CAGR 3-Years
17%
|
CAGR 5-Years
26%
|
CAGR 10-Years
23%
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Revenue
$13.1B
|
CAGR 3-Years
16%
|
CAGR 5-Years
14%
|
CAGR 10-Years
20%
|
Biomarin Pharmaceutical Inc
Revenue Breakdown
Breakdown by Geography
Biomarin Pharmaceutical Inc
Breakdown by Segments
Biomarin Pharmaceutical Inc
Total Revenue:
2.4B
USD
|
Net Product Revenues:
2.4B
USD
|
Products Excluding Aldurazyme:
2.2B
USD
|
Aldurazyme:
131.2m
USD
|
Royalty And Other Revenues:
46.7m
USD
|
See Also
What is Biomarin Pharmaceutical Inc's Revenue?
Revenue
2.5B
USD
Based on the financial report for Mar 31, 2024, Biomarin Pharmaceutical Inc's Revenue amounts to 2.5B USD.
What is Biomarin Pharmaceutical Inc's Revenue growth rate?
Revenue CAGR 10Y
16%
Over the last year, the Revenue growth was 14%. The average annual Revenue growth rates for Biomarin Pharmaceutical Inc have been 10% over the past three years , 10% over the past five years , and 16% over the past ten years .